Business, energy, technology, markets and global industry news from Business News Today

ChoICE study

PharmaDeviceNews ChoICE study
IceCure Medical’s ChoICE post-market study is evaluating the ProSense cryoablation system as a minimally invasive treatment option for eligible older patients with low-risk, early-stage breast cancer. Representative image.
Medical Devices & Diagnostics

What will IceCure Medical’s ChoICE study reveal about ProSense breast cancer cryoablation?

IceCure Medical launches the ChoICE post-market study at West Cancer Center, testing ProSense adoption and five-year outcomes in breast cancer.

Read More